Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Verrica Pharmaceuticals (VRCA) PT Lowered to $13 at RBC Capital
August 15, 2024 6:16 AM EDTRBC Capital analyst Daniel Busby lowered the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $13.00 (from $14.00) while maintaining a Outperform rating.
The analyst comments "VRCA's 2Q report shows steady progress for YCANTH through its molluscum contagiosum launch as distribution network expands; although aspects such as... More
Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c
August 14, 2024 7:46 AM EDTVerrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $4.58 million.
For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.
... More